Overview

Prostate Embolization for Benign Prostatic Hyperplasia

Status:
Recruiting
Trial end date:
0000-00-00
Target enrollment:
30
Participant gender:
Male
Summary
This is a Phase I/II investigator sponsored FDA-approved Investigational Device Exemption protocol, with the primary goal of determining the safety of prostatic artery embolization (PAE) for benign prostatic hyperplasia. Our primary goal is to document the frequency of side effects, particularly bladder and rectal complications, which may occur as a result of this procedure. Secondarily, the study will provide preliminary data to determine its effectiveness in diminishing obstructive symptoms associated with BPH.
Phase:
Phase 1/Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
James B. Spies, MD
Last Updated:
2016-07-28
Criteria
Inclusion Criteria:

1. You must have symptoms from BPH for at least 6 months

2. Your symptoms must meet the entrance criteria, as determined by a short questionnaire
you will be asked to complete.

3. You must have urinary flow rates that meet entrance criteria, as measured by a simple
urination test.

4. Enlargement of the prostate, as measured by the urologist, with a volume of between
50 and 100 cc.

5. You must be at least 50 years of age, but not more than 90.

Exclusion Criteria:

- 1. Prostate Cancer 2. Blockage of major arteries in your pelvis or other arterial
abnormalities that prevent embolization or that might increase risks of injury. You
will be screened for these conditions if you consent to participate.

3. Significantly decreased kidney function 4. Prior prostate surgery, whether it has
been performed via a scope through the penis or with conventional surgery.

5. Bladder or urinary conditions other than BPH requiring therapy. You will be
screened for these conditions if you consent to participate.

6. History of cardiac rhythm abnormalities, congestive heart failure, uncontrolled
diabetes, significant respiratory disease, or known immunosuppression.

7. History of clotting disorders. 8. Current medications (use of alpha-blockers
within two months, 5-alpha-reductase inhibitors within six months, anti-cholinergics
within two months, and beta blockers, antihistamines, anticonvulsants, or
antispasmodics within one week of treatment unless you have been on the same drug
with a stable urination pattern.

9. Active urinary tract infection 10. Allergy to iodinated contrast agents, collagen
or gelatin products 11. Acute urinary retention that has NOT been treated by a
urinary catheter. 12. Significant retained urine after voiding as measured by
ultrasound. In this case, significant means more than 250 ml (about 1 cup).

13. Bladder stones or blood in urine within three months 14. Previous rectal surgery,
excluding hemorrhoidectomy (removal of hemorrhoid), or history of rectal disease 15.
Prior pelvic irradiation or radical pelvic surgery 16. If you are interested in
future fertility 17. Unable to speak and read English.